Aerosol formulations containing propellant 134a and fluticasone propionate
AssigneeGlaxo Group Limited
InventorsRachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
Life of this patent
Estimating the term…
Abstract
This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament selected from the group comprising salmeterol, salbutamol, fluticasone propionate and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
Claims39
A pharmaceutical aerosol formulation consisting essentially of particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A pharmaceutical aerosol formulation consisting essentially of particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation is free of surfactant, the particulate medicament being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A pharmaceutical aerosol formulation consisting of particulate medicament consisting of fluticasone propionate or a physiologically acceptable solvate thereof, and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof;
- a particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof;
- and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns which formulation is free of surfactant.
A pharmaceutical aerosol formulation consisting of particulate medicament consisting of fluticasone propionate or a physiologically acceptable solvate thereof;
- particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof;
- and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof;
- a particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate, mixtures thereof and physiologically acceptable salts and solvates thereof;
- and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicaments, the particulate medicaments being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation consisting essentially of particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof, and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based on the weight of medicament, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation consisting of particulate medicament consisting of fluticasone propionate or a physiologically acceptable solvate thereof, and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicament being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation consisting essentially of particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof;
- a particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof;
- and 1,1,1,2-tetrafluoroethane as propellant which formulation contains less than 0.0001% w/w surfactant based on the weight of medicament the particulate medicaments being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation consisting of particulate medicament consisting of fluticasone propionate or a physiologically acceptable solvate thereof;
- a particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts and solvates thereof;
- and 1,1,1,2-tetrafluoroethane as propellant, the particulate medicaments being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof;
- and 1,1,1,2-tetrafluoroethane as propellant, which formulation is free of surfactant, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation consisting essentially of a particulate medicament which is fluticasone propionate or physiologically acceptable solvate thereof;
- particulate medicament selected from the group consisting of salmeterol, salbutamol, beclomethasone dipropionate and physiologically acceptable salts or solvates thereof;
- and 1,1,1,2-tetrafluoroethane as propellant, which formulation is free of surfactant, the particulate medicaments being present in an amount of 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns.
Dependencies are inferred from the claim text.